Floatz logo

Opnurasib

KRAS G12C

Maastricht University Medical CenterSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
81/ 100

Competitive context

23 Active assets in the KRAS G12C cohort.

Asset / SponsorPhaseRating
LENVATINIB
ETOP IBCSG Partners Foundation
Phase 2CCC
Sotorasib
ETOP IBCSG Partners Foundation
Phase 2CCC
Adagrasib
Ryan Gentzler, MD
Phase 2CCC
Fulzerasib
Innovent Biologics (Suzhou) Co. Ltd.
Phase 1/2CCC
Fmc-376
Frontier Medicines Corporation
Phase 1/2CC

View all 23 →

Same molecule, other indications

Opnurasib is also rated in:

non-small cell lung carcinomaDormant
BB
Indicative ·
70 / 100
View asset →
metastatic malignant neoplasm in the brainDormant
CCC
Indicative ·
53 / 100
View asset →
colorectal carcinomaDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →